08.08.11
MRSA treatment from Cempra inching toward phase 3 trials
MedCityNews
08.01.11
Alimera Sciences Appoints James R. Largent to Its Board of Directors
Press Release
07.28.11
Novel antifungal from Viamet selected for NIH rare diseases drug program
07.19.11
Semprius plans manufacturing plant
News & Observer
06.30.11
Semprius Closes On $20M In Open C Round
Dow Jones VentureWire
06.29.11
Overture Networks' Arthur Bergens Named Triangle Business Journal's "CFO of the Year" Finalist
06.01.11
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
05.24.11
Gloto Selects LOC-AID to Location-Enable Mobile/Social Consumer Experiences for Major Brands and Publishers
05.19.11
Aldagen Announces Publication of Phase 1/2 Results for ALD-301, a Stem Cell Therapy in Development for Critical Limb Ischemia
Alimera's New 36-Month Safety and Efficacy Results From the Phase 3 Fame™ Study of Iluvien® in Patients With Diabetic Macular Edema Presented at the 2011 Arvo Annual Meeting
